INT11957

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1992
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 52
Total Number 54
Disease Relevance 39.09
Pain Relevance 6.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (LPA) transport (LPA) small molecule metabolic process (LPA)
extracellular region (LPA) lipid metabolic process (LPA)
Anatomy Link Frequency
plasma 6
platelet 3
tube 1
stage 3 1
CII 1
LPA (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammatory mediators 8 100.00 Very High Very High Very High
local anesthetic 9 99.96 Very High Very High Very High
agonist 96 99.76 Very High Very High Very High
antagonist 9 99.50 Very High Very High Very High
addiction 22 99.34 Very High Very High Very High
intrathecal 1 98.96 Very High Very High Very High
Angina 30 98.76 Very High Very High Very High
Pain 15 98.72 Very High Very High Very High
cva 68 97.52 Very High Very High Very High
Inflammation 89 97.36 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 471 100.00 Very High Very High Very High
Adhesions 124 100.00 Very High Very High Very High
INFLAMMATION 116 100.00 Very High Very High Very High
Lumbar Puncture Related Headaches 33 100.00 Very High Very High Very High
Proteinuria 9 99.84 Very High Very High Very High
Metabolic Syndrome 28 99.24 Very High Very High Very High
Increased Venous Pressure Under Development 103 99.12 Very High Very High Very High
Diabetes Mellitus 431 99.08 Very High Very High Very High
Arrhythmias 2 Under Development 202 99.08 Very High Very High Very High
Cv General 3 Under Development 31 98.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There was a trend toward a decrease in mean apolipoprotein A1 levels as Lp(a) levels increased.
Negative_regulation (decrease) of apolipoprotein associated with disorder of lipid metabolism
1) Confidence 0.59 Published 2010 Journal Korean Circulation Journal Section Body Doc Link PMC2978291 Disease Relevance 0.53 Pain Relevance 0
Some reports have indicated that niacin; certain inhibitors of the cholesteryl ester transfer protein; and mipomersen, an antisense oligonucleotide directed at human apoB-100; reduce Lp(a) levels about 20%, 40%, and 70%, respectively.17-19) No patients in this study took any of these medications.
Negative_regulation (reduce) of Lp
2) Confidence 0.59 Published 2010 Journal Korean Circulation Journal Section Body Doc Link PMC2978291 Disease Relevance 0.54 Pain Relevance 0.04
The specific inhibitor PF-8380, dosed orally at 30 mg/kg, provided >95% reduction in both plasma and air pouch LPA within 3 h, indicating autotaxin is a major source of LPA during inflammation.
Negative_regulation (reduction) of LPA in plasma associated with inflammation
3) Confidence 0.49 Published 2010 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 20392816 Disease Relevance 0.94 Pain Relevance 0.56
Because local anesthetics (LA) inhibit LPA signaling and attenuate PMN responses, we also investigated the effects of LA on these actions.
Negative_regulation (inhibit) of LPA in PMN associated with local anesthetic
4) Confidence 0.37 Published 2001 Journal Anesth. Analg. Section Abstract Doc Link 11273947 Disease Relevance 0.09 Pain Relevance 0.57
Receptor-selective antagonists and agonists as well as inhibitors of LPA producing enzymes are undoubtedly useful.
Negative_regulation (inhibitors) of LPA associated with antagonist and agonist
5) Confidence 0.37 Published 2008 Journal Curr. Med. Chem. Section Abstract Doc Link 18781939 Disease Relevance 0.43 Pain Relevance 0.24
The affective state of the patients suffering from loss of psychic autoactivation (LPA) is preserved and is dampered as exhibited by a subtle examination, but depends on the same activation by the surrounding people as cognitive thought: it fades if the patient is not stimulated.
Negative_regulation (loss) of LPA associated with cognitive disorder
6) Confidence 0.37 Published 1998 Journal Rev. Neurol. (Paris) Section Abstract Doc Link 9773023 Disease Relevance 0.24 Pain Relevance 0.11
The LPA levels are lower in the control group than in the NVAF without SBI and SBI without NVAF groups (p < 0.01), however, the latter two groups did not significantly differ from each other for LPA levels (p > 0.05) There were significant differences in the positive rate of platelet activation between each of the groups (p < 0.01).
Negative_regulation (lower) of LPA in platelet associated with brain hemorrhage and arrhythmias 2 under development
7) Confidence 0.34 Published 2010 Journal International Journal of Molecular Sciences Section Abstract Doc Link PMC2996775 Disease Relevance 2.29 Pain Relevance 0.08
The LPA levels are lower in the control group than in the NVAF without SBI and SBI without NVAF groups (p < 0.01).
Negative_regulation (lower) of LPA associated with brain hemorrhage and arrhythmias 2 under development
8) Confidence 0.34 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2996775 Disease Relevance 2.53 Pain Relevance 0
Platelet depletion or treatment with anti-platelet agents reduces circulating LPA levels in animals [11,12].
Negative_regulation (reduces) of LPA in platelet
9) Confidence 0.34 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2996775 Disease Relevance 1.34 Pain Relevance 0.06
Comparable results were obtained in our recombinant model, where S(-)-bupivacaine most effectively inhibited LPA signaling.
Negative_regulation (inhibited) of LPA
10) Confidence 0.34 Published 2003 Journal Anesth. Analg. Section Abstract Doc Link 14500156 Disease Relevance 0.34 Pain Relevance 0.29
But to reduce high Lp(a) levels, the immunoadsorption method with special Lp(a) columns seems to be the most effective (-57% versus 25% [Kaneka] and 23% [Baxter]).
Negative_regulation (reduce) of Lp
11) Confidence 0.28 Published 1997 Journal Ther Apher Section Abstract Doc Link 10225781 Disease Relevance 0.68 Pain Relevance 0.07
Further, embryos lacking LPA exhibited asymmetric neural headfold, reflecting large effusions with high levels of apoptotic cells [8].
Negative_regulation (lacking) of LPA in neural associated with apoptosis
12) Confidence 0.22 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2621239 Disease Relevance 0.39 Pain Relevance 0
Eventually, the fundamental biochemical defect was determined to be a complete absence of plasma apolipoprotein (apo) B-containing lipoproteins, namely chylomicrons, very-low density lipoprotein (VLDL) and low-density lipoprotein (LDL).
Negative_regulation (absence) of apolipoprotein in plasma associated with disorder of lipid metabolism
13) Confidence 0.20 Published 2008 Journal Orphanet J Rare Dis Section Body Doc Link PMC2467409 Disease Relevance 0.80 Pain Relevance 0
With LDL apheresis, reductions of 46% for total cholesterol, 49% for LDL, 30% for Lp(a), and 38% for triglycerides were reached.
Negative_regulation (reductions) of Lp associated with disorder of lipid metabolism
14) Confidence 0.20 Published 1997 Journal Ther Apher Section Abstract Doc Link 10225781 Disease Relevance 0.70 Pain Relevance 0.10
High Lp(a) levels and decreased plasminogen levels have synergistic effects in further increasing thrombophilic risk when both are present at the same time (Müller et al 1992; Stojakovic et al 2007).
Negative_regulation (decreased) of Lp
15) Confidence 0.18 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2694013 Disease Relevance 0.56 Pain Relevance 0
The co-existence of these conditions, reflecting both a genetic link and a significant reduction in Lp(a) levels amounting to 24.71% following the administration of T. arjuna, prompted the authors to report on this case.
Negative_regulation (reduction) of Lp
16) Confidence 0.17 Published 2007 Journal J Altern Complement Med Section Abstract Doc Link 17388772 Disease Relevance 0.73 Pain Relevance 0.10
Both medications increased high-density lipoprotein cholesterol (HDL-C) with pioglitazone having no effect on serum apolipoprotein AI levels, but rosiglitazone was associated with a decrease in apolipoprotein AI levels.44,45 All these changes deem rosiglitazone to have a less favorable effect on the lipid profile compared to pioglitazone.
Negative_regulation (decrease) of apolipoprotein AI associated with disorder of lipid metabolism
17) Confidence 0.14 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2686257 Disease Relevance 0.80 Pain Relevance 0.04
No significant differences were observed in Ch, TG and HDL-C when the period of addiction increased iii) Lpa, apo B, HbA1C, CRP, SGOT, SGPT, Fibrinogen, Factor VII and LDL augmented significantly when the period of addiction increased more than 2 years but apoA decreased significantly.


Negative_regulation (decreased) of apoA associated with addiction and disorder of lipid metabolism
18) Confidence 0.12 Published 2008 Journal Lipids Health Dis Section Body Doc Link PMC2588593 Disease Relevance 1.01 Pain Relevance 0.40
is an important target of LPA [141], wherefore those authors are developing inhibitors of the LPA receptor.
Negative_regulation (inhibitors) of LPA
19) Confidence 0.10 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2829540 Disease Relevance 0.43 Pain Relevance 0.24
In women Lp(a) decreased, however, in response to the A- and increased to B formulation which was opposite the results in men where the increase was seen in A.
Negative_regulation (decreased) of Lp
20) Confidence 0.10 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2768711 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox